Week of Mar. 26, 2012: Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Week of Mar. 26, 2012: Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Abbott has announced that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the latest milestone in the process that began in October 2011, when Abbott announced it would separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. AbbVie will include Abbott’s current portfolio of proprietary pharmaceuticals and biologics. Read More

Catalent Pharma Solutions has completed its new development and analytical solutions’ laboratories at its facility in Swindon, United Kingdom. From this new laboratory suite, Catalent will offer analytical testing, development support, and regulatory services to pharmaceutical and biopharmaceutical companies. The laboratory suite incorporates expanded facilities for the storage and testing of controlled and cytotoxic substances. Catalent’s new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European import testing, qualified person and regulatory consulting services, methods development, and microbial, sterility, and stability testing for a range of advanced-dose forms, including for inhaled and orally administered substances. Read More

Novasep, a supplier of manufacturing solutions to the life-sciences industries, has opened a new 2000-m2 (21,527.820 ft2) facility in Shanghai, China. The site is intended to increase Novasep’s process-development and engineering capabilities to meet increasing Chinese and East Asian demand. The facilities will also add to Novasep’s existing 12 global synthesis and process sites in the US, France, Germany, Belgium, and the Bahamas. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here